Filing summary
Entity and period: The supplied filing is DelMar Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended December 31, 2014—not a filing identified as Tuhura Biosciences, Inc. The company is an early-stage cancer drug developer. Its lead candidate, VAL-083, was in a Phase I/II trial for refractory glioblastoma (GBM). The company reported no product revenue.
Financial performance and liquidity
| Metric | Period / date | Value |
|---|---|---|
| Research and development expense | Six months ended Dec. 31, 2014 | $1.284 million |
| General and administrative expense | Six months ended Dec. 31, 2014 | $1.101 million |
| Net loss | Six months ended Dec. 31, 2014 | $2.399 million; $0.06 per share |
| Cash used in operating activities | Six months ended Dec. 31, 2014 | $2.065 million |
| Cash and cash equivalents | Dec. 31, 2014 | $3.958 million |
| Working capital | Dec. 31, 2014 | $3.834 million |
| Derivative liability | Dec. 31, 2014 | $1.567 million |
| Total stockholders’ equity | Dec. 31, 2014 | $2.087 million |
No revenue or operating margin was reported. The company had no conventional debt at period-end: a $278,530 loan from Valent was exchanged for Series A preferred shares in September 2014. The preferred shares carry a 3% annual dividend and a liquidation preference. Cash increased by $1.264 million from warrant-exercise proceeds, but declined by $801,272 overall during the six months.
Changes versus the prior comparable period
- Six-month R&D expense increased 14% to $1.284 million, reflecting clinical, preclinical and intellectual-property activity. G&A expense declined 20% to $1.101 million, largely due to lower share-based compensation and professional fees.
- The company reported a $2.399 million loss, compared with $5.928 million of income in the prior-year six-month period. The prior-year result included an $8.467 million noncash gain from revaluing warrant-related derivative liabilities; the current period included a $66,606 gain from that revaluation.
- Cash was down from $4.760 million at June 30, 2014. Stockholders’ equity increased from $880,479, while the derivative liability fell from $3.329 million, primarily reflecting warrant exercises, exchanges and amendments.
Outlook, developments and risks
- Management estimated existing resources would fund operations through at least the end of the first quarter of calendar 2016, while stating that continued operations and development depend on securing additional financing. Management cautioned that estimates may prove inaccurate and that programs may be delayed, reduced or discontinued if funding is unavailable.
- In January 2015, the company announced the first dose-limiting toxicity in its GBM dose-escalation study, at 50 mg/m². It expected to clarify the maximum tolerated dose during the first half of calendar 2015; future registration-directed trials would require additional funding and FDA discussions.
- The company described nonclinical work supporting possible VAL-083 development in non-small cell lung cancer and targeted a China study around mid-2015 under a collaboration in which Guangxi Wuzhou Pharmaceuticals would bear the China trial costs. This was a plan, not a completed milestone.
- Warrant valuations rely on Level 3 estimates and share-price movements can materially affect reported earnings. Warrant transactions also created dilution: 1,986,074 warrants were exercised during the six months, and 414,889 common shares were issued in exchange for 1,244,666 warrants. A subsequent tender offer exchanged another 1,591,875 warrants for 530,625 shares.
- Other risks include no near-term product revenue, dependence on financing, clinical and regulatory uncertainty, reliance on a single supplier for VAL-083, and intellectual-property protection concerns in China. The filing reported no legal proceedings and stated disclosure controls were effective.
Important facts to verify
- Confirm the entity: the filing names DelMar Pharmaceuticals, Inc., whereas the request metadata names Tuhura Biosciences, Inc.
- Reconcile R&D expense for the quarter: the financial statements report $612,169, while MD&A comparison text gives $566,060 and a selected-data table gives $560,060.
- Check the cash runway assumptions and financing plans, particularly the funding needed for registration-directed GBM studies.
- Review the clinical-trial data, dose-limiting toxicity details, planned maximum-tolerated-dose decision and subsequent FDA interactions.
- Assess dilution and warrant-related accounting, including post-quarter tender-offer exchanges and the Level 3 valuation assumptions.